Statement of Principles concerning malignant neoplasm of bone and articular cartilage No. 107 of 2011

Administered by Department of Veterans' Affairs

Legislation au F2011L01740 Not in force Legislative Instrument

Legislation content

Statement of Principles concerning malignant neoplasm of bone and articular cartilage No. 107 of 2011

made under subsection 196B(3) of the

Veterans' Entitlements Act 1986

Compilation No. 1  

Compilation date:   18 September 2017

Includes amendments up to: Veterans' Entitlements (Statements of Principles—Cumulative Equivalent Dose) Amendment Determination 2017 (No. 58 of 2017) (F2017L01067)

The day of commencement of this Amendment Determination is 18 September 2017.

 

About this compilation

 

This compilation

This is a compilation of the Statement of Principles concerning malignant neoplasm of bone and articular cartilage No. 107 of 2011 that shows the text of the law as amended and in force on 18 September 2017.

The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.

Application, saving and transitional provisions for provisions and amendments

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.

Selfrepealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

 

 

 

 

 

 

Statement of Principles

concerning

 

MALIGNANT NEOPLASM OF BONE AND ARTICULAR CARTILAGE

No. 107 of 2011

 

for the purposes of the

 

Veterans’ Entitlements Act 1986

and

Military Rehabilitation and Compensation Act 2004

 

Title

1. This Instrument may be cited as Statement of Principles concerning malignant neoplasm of bone and articular cartilage No. 107 of 2011.

 

Determination

2. The Repatriation Medical Authority under subsection 196B(3) and (8) of the Veterans’ Entitlements Act 1986 (the VEA):

(a) revokes Instrument No. 41 of 2002 concerning malignant neoplasm of the bone or articular cartilage; and

(b) determines in its place this Statement of Principles.

 

Kind of injury, disease or death

3. (a) This Statement of Principles is about malignant neoplasm of bone and articular cartilage and death from malignant neoplasm of bone and articular cartilage.

(b)              For the purposes of this Statement of Principles, "malignant neoplasm of bone and articular cartilage" means a primary malignant neoplasm arising in bone or articular cartilage. This definition excludes extraskeletal soft tissue sarcoma and malignant neoplasms of haematopoietic tissue.

(c)               Malignant neoplasm of bone and articular cartilage attracts ICD-10-AM code C40 or C41.

(d)              In the application of this Statement of Principles, the definition of "malignant neoplasm of bone and articular cartilage" is that given at paragraph 3(b) above.

 

Basis for determining the factors

4. On the sound medical-scientific evidence available, the Repatriation Medical Authority is of the view that it is more probable than not that malignant neoplasm of bone or articular cartilage and death from malignant neoplasm of bone or articular cartilage can be related to relevant service rendered by veterans or members of the Forces under the VEA, or members under the Military Rehabilitation and Compensation Act 2004 (the MRCA).

 

Factors that must be related to service

5. Subject to clause 7, at least one of the factors set out in clause 6 must be related to the relevant service rendered by the person.

 

Factors

6. The factor that must exist before it can be said that, on the balance of probabilities, malignant neoplasm of bone or articular cartilage or death from malignant neoplasm of bone or articular cartilage is connected with the circumstances of a person’s relevant service is:

 

(a)                having received a cumulative equivalent dose of at least 0.5 sievert of ionising radiation to the affected region at least five years before the clinical onset of malignant neoplasm of bone or articular cartilage; or

 

(b)               for osteosarcoma and fibrosarcoma only, having Paget’s disease of bone at the affected site before the clinical onset of malignant neoplasm of bone or articular cartilage; or

 

(c)                for fibrosarcoma and angiosarcoma only, having chronic osteomyelitis at the affected site before the clinical onset of malignant neoplasm of bone or articular cartilage; or

 

(d)               inability to obtain appropriate clinical management for malignant neoplasm of bone or articular cartilage.

 

Factors that apply only to material contribution or aggravation

7. Paragraph 6(d) applies only to material contribution to, or aggravation of, malignant neoplasm of bone or articular cartilage where the person’s malignant neoplasm of bone or articular cartilage was suffered or contracted before or during (but not arising out of) the person’s relevant service.

 

Inclusion of Statements of Principles

8.                   In this Statement of Principles if a relevant factor applies and that factor includes an injury or disease in respect of which there is a Statement of Principles then the factors in that last mentioned Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.

 

Other definitions

9.                   For the purposes of this Statement of Principles:

"cumulative equivalent dose" means the total dose of ionising radiation received by the particular organ or tissue from external exposure, internal exposure or both, apart from normal background radiation exposure in Australia, calculated in accordance with the methodology set out in Guide to calculation of 'cumulative equivalent dose' for the purpose of applying ionising radiation factors contained in Statements of Principles determined under Part XIA of the Veterans' Entitlements Act 1986 (Cth), Australian Radiation Protection and Nuclear Safety Agency, as in force on 2 August 2017;

Note 1: Examples of circumstances that might lead to exposure to ionising radiation include being present during or subsequent to the testing or use of nuclear weapons, undergoing diagnostic or therapeutic medical procedures involving ionising radiation, and being a member of an aircrew, leading to increased levels of exposure to cosmic radiation.

Note 2: For the purpose of dose reconstruction, dose is calculated as an average over the mass of a specific tissue or organ. If a tissue is exposed to multiple sources of ionising radiation, the various dose estimates for each type of radiation must be combined.

 

"death from malignant neoplasm of bone or articular cartilage" in relation to a person includes death from a terminal event or condition that was contributed to by the person’s malignant neoplasm of bone or articular cartilage;

 

"ICD-10-AM code" means a number assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Australian Modification (ICD-10-AM), Seventh Edition, effective date of 1 July 2010, copyrighted by the National Centre for Classification in Health, Sydney, NSW, and having ISBN 978 1 74210 154 5;

 

"relevant service" means:

(a)              eligible war service (other than operational service) under the VEA; or

(b)              defence service (other than hazardous service) under the VEA; or

(c)              peacetime service under the MRCA;

 

"terminal event" means the proximate or ultimate cause of death and includes:

(a) pneumonia;

(b) respiratory failure;

(c) cardiac arrest;

(d) circulatory failure; or

(e)                cessation of brain function.

 

Application

10. This Instrument applies to all matters to which section 120B of the VEA or section 339 of the MRCA applies.

 

Date of effect

11. This Instrument takes effect from 31 August 2011.

 

 

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

Abbreviation key—Endnote 2

The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Misdescribed amendments

A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.

If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history. 

Endnote 2—Abbreviation key

 

o = order(s)

ad = added or inserted

Ord = Ordinance

am = amended

orig = original

amdt = amendment

par = paragraph(s)/subparagraph(s)

c = clause(s)

    /subsubparagraph(s)

C[x] = Compilation No. x

pres = present

Ch = Chapter(s)

prev = previous

def = definition(s)

(prev…) = previously

Dict = Dictionary

Pt = Part(s)

disallowed = disallowed by Parliament

r = regulation(s)/rule(s)

Div = Division(s)

 

exp = expires/expired or ceases/ceased to have

reloc = relocated

    effect

renum = renumbered

F = Federal Register of Legislation

rep = repealed

gaz = gazette

rs = repealed and substituted

LA = Legislation Act 2003

s = section(s)/subsection(s)

LIA = Legislative Instruments Act 2003

Sch = Schedule(s)

(md) = misdescribed amendment can be given

Sdiv = Subdivision(s)

    effect

SLI = Select Legislative Instrument

(md not incorp) = misdescribed amendment

SR = Statutory Rules

    cannot be given effect

SubCh = SubChapter(s)

mod = modified/modification

SubPt = Subpart(s)

No. = Number(s)

underlining = whole or part not

 

    commenced or to be commenced

 

Endnote 3—Legislation history

 

Name

Registration

Commencement

Application, saving and transitional provisions

Statement of Principles concerning malignant neoplasm of bone and articular cartilage No. 107 of 2011

 

26 August 2011

 

F2011L01740

31 August 2011

 

 

Veterans' Entitlements (Statements of Principles—Cumulative Equivalent Dose) Amendment Determination 2017 (No. 58 of 2017)

 

22 August 2017

 

F2017L01067

 

18 September 2017

 

 

 

Endnote 4—Amendment history

 

Provision affected

How affected

Clause 9 – ' "cumulative equivalent dose"……'

rs. Instrument  No. 58 of 2017

 

 

Overview

The Statement of Principles concerning malignant neoplasm of bone and articular cartilage No. 107 of 2011 was enacted to address the relationship between malignant neoplasms of bone and articular cartilage and the service rendered by veterans or members of the Forces under the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. This legislative instrument was issued by the Repatriation Medical Authority under the authority of the Veterans' Entitlements Act 1986. It revokes the previous Statement of Principles No. 41 of 2002 and establishes new criteria for determining the connection between these malignant neoplasms and service. The policy objective is to ensure that veterans and members of the Forces who have developed malignant neoplasms of bone and articular cartilage, or who have died from such neoplasms, receive appropriate consideration for their entitlements and compensation. This Statement of Principles aims to provide a clear framework for assessing the likelihood that malignant neoplasms of bone or articular cartilage are related to relevant service. It identifies specific factors that must be considered, such as exposure to ionising radiation, pre-existing conditions like Paget’s disease or chronic osteomyelitis, and the inability to obtain appropriate clinical management. The Statement of Principles also incorporates relevant factors from other Statements of Principles if applicable, ensuring a comprehensive evaluation of each case. The instrument came into effect on 31 August 2011, providing a legal basis for the Repatriation Medical Authority to determine the service connection for malignant neoplasms of bone and articular cartilage.

Scope and Application

This legislative instrument, Statement of Principles concerning malignant neoplasm of bone and articular cartilage No. 107 of 2011, applies to all matters to which section 120B of the Veterans' Entitlements Act 1986 (VEA) or section 339 of the Military Rehabilitation and Compensation Act 2004 (MRCA) applies. This includes veterans, members of the Australian Defence Force, and individuals who have rendered service under the VEA or MRCA. The instrument specifically addresses malignant neoplasm of bone and articular cartilage and death from such conditions, with the definition of "malignant neoplasm of bone and articular cartilage" excluding extraskeletal soft tissue sarcoma and malignant neoplasms of haematopoietic tissue. The instrument outlines certain factors that must be related to the relevant service rendered by the person to establish a connection between the condition and service, such as receiving a cumulative equivalent dose of at least 0.5 sievert of ionising radiation to the affected region at least five years before the clinical onset of malignant neoplasm of bone or articular cartilage. The instrument came into effect on 31 August 2011 and was subsequently amended on 18 September 2017 by the Veterans' Entitlements (Statements of Principles—Cumulative Equivalent Dose) Amendment Determination 2017 (No. 58 of 2017).

Key Provisions

The Statement of Principles concerning malignant neoplasm of bone and articular cartilage No. 107 of 2011, made under subsection 196B(3) of the Veterans' Entitlements Act 1986, establishes the criteria and conditions for linking malignant neoplasm of bone and articular cartilage, including death resulting from such neoplasms, to the relevant service of veterans or members of the Armed Forces. This legislative instrument revokes the previous Statement of Principles No. 41 of 2002 and replaces it with the current one, effective from 31 August 2011. The primary focus of this Statement of Principles is to determine the relationship between malignant neoplasm of bone and articular cartilage and the service rendered by veterans or members of the Armed Forces, based on medical-scientific evidence. Under this Statement of Principles, the Repatriation Medical Authority determines that malignant neoplasm of bone or articular cartilage and death from such neoplasms can be related to relevant service. For a connection to be established, at least one of the specified factors must be related to the relevant service. These factors include receiving a cumulative equivalent dose of at least 0.5 sievert of ionising radiation to the affected region at least five years before the clinical onset of the neoplasm, having Paget’s disease of bone for osteosarcoma and fibrosarcoma, having chronic osteomyelitis for fibrosarcoma and angiosarcoma, or being unable to obtain appropriate clinical management for the neoplasm. The Statement of Principles also imposes obligations on the parties it governs. It requires that any relevant factor that includes an injury or disease for which there is an existing Statement of Principles must adhere to the terms of that Statement of Principles as in force from time to time. Additionally, the factors related to material contribution or aggravation of malignant neoplasm of bone or articular cartilage apply only where the neoplasm was suffered or contracted before or during (but not arising out of) the person's relevant service. Any breaches of the provisions set out in this Statement of Principles may result in various civil or criminal consequences depending on the nature and severity of the breach. However, the specific offences, penalties, or consequences for breach are not detailed within the text of the Statement of Principles itself. It is important to note that the compiled law as shown in this document operates as modified by other laws, though the text of the law is not amended to reflect these modifications. This compilation does not include application, saving, or transitional provisions that may affect the operation of the law, and any such provisions are detailed in the endnotes.

Legal classification tags

Instrument
Legislative Instrument
Concepts
Definitions & Interpretation
Regulatory Standards
Reporting & Disclosure Obligations
Catchwords
malignant neoplasm of bone and articular cartilage
cumulative equivalent dose

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.